Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €12.74 EUR
Change Today -0.402 / -3.06%
Volume 0.0
As of 10:54 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

zealand pharma a/s (22Z) Snapshot

Open
€13.02
Previous Close
€13.14
Day High
€13.11
Day Low
€12.68
52 Week High
03/23/15 - €16.28
52 Week Low
10/17/14 - €7.78
Market Cap
298.3M
Average Volume 10 Days
3.0
EPS TTM
--
Shares Outstanding
23.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZEALAND PHARMA A/S (22Z)

Related News

No related news articles were found.

zealand pharma a/s (22Z) Related Businessweek News

No Related Businessweek News Found

zealand pharma a/s (22Z) Details

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide medicines in Denmark. It offers Lyxumia (Lixisenatide), a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes. The company is also developing Lantus (LixiLan), which is in Phase III clinical trials for the treatment of type 2 diabetes; Danegaptide that is in Phase II clinical trials to treat cardiac reperfusion injuries; and Elsiglutide, a GLP-2 receptor agonist, which is in Phase IIb clinical trials for the treatment of chemotherapy-induced diarrhea in patients with colorectal cancer. In addition, it is developing ZP4207 that is in Phase I clinical trials to treat hypoglycemia in diabetes; and ZP2929, a dual acting glucagon/GLP-1 peptide receptor agonist, which is in Phase I clinical trials for the treatment of diabetes and/or obesity. The company has license agreements and partnerships with Sanofi S.A., Helsinn Healthcare S.A., Boehringer Ingelheim International GmbH, and Eli Lilly. Zealand Pharma A/S was founded in 1997 and is based in Copenhagen, Denmark.

103 Employees
Last Reported Date: 03/13/15
Founded in 1997

zealand pharma a/s (22Z) Top Compensated Officers

Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: kr2.1M
Compensation as of Fiscal Year 2014.

zealand pharma a/s (22Z) Key Developments

Zealand Pharma A/S Announces Unaudited Consolidated Earnings Results for First Quarter Ended March 31, 2015 ; Maintains Financial Guidance for the Year 2015

Zealand Pharma A/S announced unaudited consolidated earnings results for first quarter ended March 31, 2015. For the quarter, the company reported revenue of DKK 6,339,000, operating loss of DKK 49,513,000, loss from ordinary activities before tax of DKK 55,548,000, net loss for the period of DKK 55,548,000 or DKK 2.45 per basic and diluted share, cash flows used in operating activities of DKK 61,059,000, purchase of property, plant and equipment of DKK 455,000 compared to the revenue of DKK 84,997,000, operating profit of DKK 28,608,000, profit from ordinary activities before tax of DKK 28,850,000, net profit for the period of DKK 28,850,000 or DKK 1.13 per basic and diluted share, cash flow from operating activities of DKK 40,807,000, purchase of property, plant and equipment of DKK 1,683,000 for the same quarter a year ago. The company maintains its financial guidance for 2015 as announced in the full year announcement and annual report for 2014 on 13 March 2015. This includes expectations of growing royalty revenue from Sanofi's global sales of Lyxumia(r). No specific guidance on the level of 2015 royalties can be provided, as Sanofi has given no guidance on full-year sales of Lyxumia(r). Additional revenue of up to DKK 140 million /EUR 19 million may be received from event driven milestones from partners. Net operating expenses in 2015 are expected at a range of DKK 225 million - DKK 235 million /EUR 30 million - EUR 32 million.

Zealand Pharma A/S Names Rosemary Crane as Vice Chairman of the Board

Zealand Pharma A/S announced that, in May 2015, Rosemary Crane was named Vice Chairman of the board.

Zealand Pharma A/S Starts Clinical Development of Multiple-Dose Version of its Stable Glucagon Analogue, ZP4207

Zealand Pharma A/S announced that it has advanced a multiple-dose version of its novel stable glucagon analogue, ZP4207, into clinical development. The ZP4207 multiple-dose version is for the treatment of mild to moderate hypoglycemia in diabetes patients, and could also be an essential component in a dual-hormone artificial pancreas system. ZP4207 is invented and wholly owned by Zealand. The new clinical development program with the multiple- dose version of ZP4207 will run in parallel with Zealand's ongoing clinical development program with ZP4207 as a single-use rescue pen for the treatment of severe hypoglycemia events in diabetes patients on insulin treatment. The new Phase Ib clinical trial initiated with ZP4207 is a randomized, double blind and placebo-controlled study to evaluate primarily the safety and tolerability of the compound after multiple dosing. Secondary endpoints will measure the pharmacokinetics and pharmacodynamics (blood sugar levels) of ZP4207 after multiple dosing. The trial is conducted at a clinical diabetes center in Germany and is planned to enroll 24 healthy volunteers, who will receive three different cohorts of daily doses of ZP4207, each over 5 days. Results from this study is expected in the second half of 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
22Z:GR €12.74 EUR -0.402

22Z Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 22Z.
View Industry Companies
 

Industry Analysis

22Z

Industry Average

Valuation 22Z Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.5x
Price/Book 7.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZEALAND PHARMA A/S, please visit zealandpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.